Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer takes BNP (B-type natriuretic peptide) assay to smaller laboratories:

This article was originally published in Clinica

Executive Summary

Bayer Diagnostics is expanding the availability of its BNP assay, used to help diagnose heart failure, to small-volume laboratories. After launching the test in the US in 2003 for use on the ADVIA Centaur system used in larger labs, the company is now offering it for use on the ACS:180 immunoassay system in the US and other markets. BNP (B-type natriuretic peptide) testing is gathering pace following findings that elevated levels in the blood can indicate heart failure. Similar tests are already offered in the US by Roche Diagnostics and Biosite, and several others are being developed by other companies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057092

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel